Human Monocytes - CD14, CD16 - Ziegler-Heitbrock

Contact

Lower IL-7 Receptor Expression of Monocytes Impairs Antimycobacterial Effector Functions in Patients with Tuberculosis.

Abstract

Altered monocyte differentiation and effector functions characterize immune pathogenesis of tuberculosis. IL-7 is an important factor for proliferation of T cells and impaired IL-7 sensitivity due to decreased IL-7 receptor alpha-chain (IL-7Ralpha) expression was found in patients with acute tuberculosis. Peripheral blood monocytes have moderate IL-7Ralpha expression and increased IL-7Ralpha levels were described for inflammatory diseases. In this study, we investigated a potential role of IL-7 and IL-7Ralpha expression for monocyte functions in tuberculosis. We analyzed the phenotype of monocytes in the blood from tuberculosis patients (n = 33), asymptomatic contacts of tuberculosis patients (contacts; n = 30), and healthy controls (n = 20) from Ghana by multicolor flow cytometry. Mycobacterial components were analyzed for their capacity to induce IL-7Ralpha expression in monocytes. Functional effects of monocyte to IL-7 were measured during signaling and by using an antimycobacterial in vitro kill assay. Monocytes were more frequent in peripheral blood from patients with tuberculosis and especially higher proportions of CD14+/CD16+ (M1/2) monocytes with increased PD-L1 expression characterized acute tuberculosis. IL-7Ralpha expression was decreased particularly on M1/2 monocytes from patients with tuberculosis and aberrant low expression IL-7Ralpha correlated with high PD-L1 levels. Constitutive low pSTAT5 levels of monocytes ex vivo and impaired IL-7 response confirmed functionally decreased monocyte IL-7 sensitivity of patients with tuberculosis. Mycobacteria and mycobacterial cell wall components induced IL-7 receptor expression in monocytes and IL-7 boosted mycobacterial killing by monocyte-derived macrophages in vitro. We demonstrated impaired monocyte IL-7 receptor expression as well as IL-7 sensitivity in tuberculosis with potential effects on antimycobacterial effector functions.

Authors: Adankwah E, Harelimana JD, Minadzi D, Aniagyei W, Abass MK, Batsa Debrah L, Owusu DO, Mayatepek E, Phillips RO, Jacobsen M,
Journal: J Immunol; 2021 May 15;206(10):2430-2440 doi:10.4049/jimmunol.2001256
Year: 2021
PubMed: PMID: 33911006 (Go to PubMed)